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Hepatitis C virus (HCV) infects B-lymphocytes, provokes cellular dysfunction and causes
lymphoproliferative  diseases such as cryoglobulinemia and non-Hodgkin’s B-cell lym-
phoma.  In the present study, we investigated the serum levels of kappa and lambda free
light  chains (FLC) of immunoglobulins and the kappa/lambda FLC ratio in Brazilian patients
with  chronic HCV infection and cryoglobulinemia. We  also analyzed the immunochemi-
cal  composition of the cryoglobulins in these patients. Twenty-eight cryoglobulinemic HCV
patients composed the target group, while 37 HCV patients without cryoglobulinemia were
included  as controls. The median levels of kappa and lambda FLC were  higher in patients
with  cryoglobulinemia compared to controls (p = 0.001 and p = 0.003, respectively), but the
kappa/lambda  FLC ratio was similar in patients with and without cryoglobulinemia (p > 0.05).
The median FLC ratio was higher in HCV patients presenting with advanced ﬁbrosis of the
liver  compared to HCV patients without ﬁbrosis (p = 0.004). Kappa and lambda FLC levels
were strongly correlated with the IgA, IgG and IgM levels in the patients with cryoglobu-
linemia.  In patients without cryoglobulinemia, the kappa FLC level was only correlated with
the IgG level, whereas the lambda FLC were weakly correlated with the IgA, IgG and IgM
levels.  An immunochemical pattern of mixed cryoglobulins (MC), predominantly IgM, IgG,
IgA  and kappa light chain, was veriﬁed in these immune complexes. We concluded thatHCV-infected patients presenting cryoglobulinemia have vigorous polyclonal B-lymphocyte
activation  due to chronic HCV infection and persistent immune stimulation.
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ntroduction
he chronic infection caused by hepatitis C virus (HCV) is
haracterized by both hepatic and extrahepatic clinical mani-
estations,  and the latter are primarily caused by the ability
f  HCV to infect B lymphocytes. Mixed cryoglobulinemia
MC) and B-cell non-Hodgkin lymphoma (B-NHL) are among
he  main extrahepatic manifestations of chronic hepatitis C
hat  are associated with lymphoproliferation. Cryoglobulins
n  chronic hepatitis C patients are cryoprecipitable immune
omplexes that contain IgM rheumatoid factor (IgM anti-IgG),
CV-RNA and core proteins associated with the IgG antibod-
es  that are produced during the immune response of B-cells
gainst  HCV antigens. Interestingly, MC  has been classiﬁed
s  a benign lymphoproliferative disorder that is observed in
 substantial proportion of HCV-infected patients, but it can
volve  to B-NHL. B-NHL is highly prevalent in chronic hepatitis
 patients, but efﬁcient HCV antiviral therapy causes the dis-
ppearance  of the biomarkers that are associated with clonal
ymphocyte  activation and promotes the regression of some
ypes  of HCV-associated lymphomas.1–9
Recently, the serum levels of kappa and lambda free light
hains  (FLC) of immunoglobulin have been used to diagnose
nd  monitor plasma cell dyscrasias and have been proposed
s  biomarkers of immune stimulation and inﬂammation.10,11
erum FLC levels are determined by immunonephelometry
sing sheep polyclonal antibodies that recognize epitopes
n  free kappa and lambda chains, which are hidden when
ight  and heavy chains are associated in the immunoglobu-
in molecule. Moreover, this sensitive immunoassay is able
o  detect very low concentrations of FLC (3–4 mg/L) and is
n  effective substitute for immunoﬁxation electrophoresis
IFE), which has an analytical sensitivity of only 100–150 mg/L
f  FLC, for use in the diagnosis of B- and plasma cell
yscrasias.12,13
Patients who  are chronically infected with HCV can present
n  increased level of FLC and a signiﬁcant alteration in their
LC  ratio, which has been associated with both MC and B-
HL.14,15 Although we have shown that Brazilian patients
ith chronic HCV infection present a high prevalence of cryo-
lobulinemia, no studies have been conducted to investigate
arkers of B-cell malignancies in these subjects.16,17
The aim of the present work was  to investigate the serum
evels  of kappa and lambda FLC, the kappa/lambda FLC ratio,
nd  the immunochemical composition of cryoglobulins in
razilian  patients with chronic HCV infection and cryoglob-
linemia.
aterials  and  methods
atients
ixty-ﬁve untreated HCV patients (29 women and 36 men)
ere  included in this study. The presence of chronic HCV
nfection  in these individuals was  conﬁrmed by clinical
xamination, positive anti-HCV serology, presence of serum
CV-RNA,  and HCV genotyping. Clinical manifestations of
ixed  cryoglobulinemia, such as joint involvement, myalgias,
atigue,  cutaneous vasculitis, renal immune-complex disease,4;1 8(6):638–642  639
or  peripheral neuropathy were not observed in these subjects.
Twenty  healthy volunteers (10 men  and 10 women) of similar
ages  were used to validate the international reference val-
ues  used in the FLC determination. The Ethical Committee
for  Human Research of the Professor Edgard Santos Hospital
approved the study.
Cryoglobulinemia  and  NOSA
Cryoglobulinemia was assessed using tube and gel-diffusion
cryoprecipitation18 (OKAZAKI et al., 1998). Serum levels
of  rheumatoid factor (normal value < 20 IU/mL) were  deter-
mined  by nephelometry (Immage  immunochemistry system,
Beckman-Coulter, Brea, CA, USA). Serum antinuclear anti-
body  (ANA) and antibodies against smooth muscle (ASMA) and
LKM1  antigen were tested using an indirect ﬂuorescent anti-
body  test (Viro-Immun, Labor-Diagnostika GmbH, Oberursel,
Germany).
Liver  histology
The presence of liver ﬁbrosis and liver necroinﬂammatory
activity was  ascertained in accordance with the METAVIR
protocol.19
Free  light  chains  (FLC)
Serum levels of immunoglobulins were determined by
nephelometry using the Immage  immunochemistry sys-
tem  (Beckman-Coulter, USA). Serum levels of kappa and
lambda  free light chains (kappa and lambda FLC) were
determined using the same method with Freelite® kits
(The  Binding Site, Birmingham, UK). The normal ranges
for  FLC were  3.3–19.4 mg/L and 5.7–26.3 mg/L for the kappa
and  lambda chains, respectively, whereas the normal range
of  the free kappa to lambda chain ratio was  0.3–1.65.20
These normal ranges were validated in 20 healthy individ-
uals  from the same population of HCV patients (99% CI:
kappa  FLC = 10.85–15.05 mg/L, lambda FLC = 13.95–18.16 mg/L
and  FLCr = 0.71–0.92).
Immunoﬁxation  (IFE)
The IMMUNOFIX® kit (The Binding Site, Birmingham, UK)  was
used  to detect and identify the immunoglobulins and their
light  chains in solubilized cryoglobulins and to evaluate the
presence  of monoclonal immunoglobulins in this material.
Statistical  analysis
The results were  expressed as the mean ± standard deviation
(SD)  or the median and interquartile range (IQR = Q1–Q3), in
accordance  with their distribution in the D’Agostino-Pearson
test. The Mann–Whitney U test was used to compare the medi-
ans  of two groups, whereas their means were compared using
unpaired  Student’s t test. Correlation between two variables
was  assessed by the Spearman test, while the association
between two categorical groups was analyzed using Fisher’s
exact  test. The Prism 6.0 software from GraphPad (USA) was
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Table 1 – Demographic, virologic, and clinical aspects of
HCV-infected patients.
Characteristic Non-cryoglobulin
(n 37)
Cryoglobulin
(n 28)
Gender (men/women) 20/17 16/12
Age (years) 47.3 ± 9.8 51.9 ± 8.6
Genotype
Genotype 1 27/33 (81.8%) 14/25 (56.0%)
Genotype 2 2/33  (6.1%) None
Genotype 3 4/33  (12.1%) 10/25 (40.0%)
Genotype 4 None  1/25 (4.0%)
Table 3 – Immunochemical composition of cryoglobulins
from HCV-infected patients.
Ig isotype Immunoﬁxation electrophoresis
(n = 17)
A/G/M// 1 (6.0%)
A/G/M/ 3 (18.0%)
A/G/ 1 (6.0%)
G/M/ 7 (40.0%)
G/M// 2 (12.0%)Fibrosis (METAVIR)
F0–F2  22/28 (78.6%) 8/24 (33.3%)
F3–F4 6/28 (21.4%) 16/24 (66.7%)
used for the statistical analyses, and the signiﬁcance level was
set  at p < 0.05.
Results
Clinical  and  demographic  characteristics
Most patients were  infected with HCV genotype 1, followed
in  prevalence by infection with HCV genotype 3. HCV geno-
types  2 and 4 were  rarely observed. Serum cryoglobulinemia
was  observed in 43.1% (28/65) patients. Nineteen (67.9%) of
these  cryoglobulinemic individuals had positive rheumatoid
factor  (median 49.5 IU/mL, IQR = 24.0–104.0 IU/mL), whereas
signiﬁcant levels of this autoantibody were found in
18  of the 37 (48.60%) patients without cryoglobulinemia
(median = 26.3 IU/mL, IQR = 22.6–41.3 IU/mL) (p > 0.05).
Three of the 65 (<10.0%) patients had antinuclear antibod-
ies,  whereas ASMA was  detected in low titers in 28 (43.1%)
patients. LKM1 antibodies were not found.
Liver ﬁbrosis varied from F1 to F4 but was  absent in one
of  the HCV-infected subjects. Sixteen of the 24 (66.7%) cryo-
globulinemic patients had advanced ﬁbrosis (F3–F4), while this
condition was  only observed in six of the 28 (21.4%) patients
without  cryoglobulinemia (p = 0.002) (see Table 1).
Serum  levels  of  immunoglobulin  and  free  light  chainsCryoglobulinemic patients had higher levels of IgA and IgM
than  did patients without cryoglobulins (p = 0.004 and p = 0.014,
respectively).  However, no difference was  observed in their IgG
levels  (p > 0.05).
Table 2 – Serum levels of immunoglobulins and kappa and lam
and HCV-infected patients.
Ig and FLC Non-cryoglobulin  
IgA 253.7 ± 122.0 
IgG 1719 ± 498.7 
IgM 113.0 (77.4–156.5) 
Kappa FLC 13.3 (10.1–17.6) 
Lambda FLC 17.0 (14.2–19.8) 
FLC ratio 0.79 (0.70–0.93) 
The immunoglobulin level is presented as the mean ± SD (mg/dL) and theG/ 2 (12.0%)
M/ 1 (6.0%)
Patients with and without cryoglobulins differed in their
median  levels of kappa and lambda FLC (p = 0.001 and p = 0.003,
respectively). A higher frequency of elevated kappa FLC levels
was  observed in patients with cryoglobulinemia (13/28, 46.4%)
than  in patients without cryoglobulins (7/37, 18.9%; p = 0.029).
The  serum levels of kappa FLC were positively correlated
with the serum levels of IgA (r = 0.55, p = 0.003), IgG (r = 0.70,
p  < 0.0001), and IgM (r = 0.57, p = 0.002) in cryoglobulinemic
patients, whereas this correlation was observed only between
the  kappa FLC and IgG levels in patients without cryoglobulins
(r  = 0.51, p = 0.001). Similar correlations were  observed between
the  serum levels of lambda FLC and IgA (r = 0.61, p = 0.001),
IgG  (r = 0.67, p < 0.0001) and IgM (r = 0.62, p = 0.001) in patients
with  cryoglobulinemia. These correlations were  weaker in
patients  without cryoglobulins (IgA, r = 0.37, p = 0.026; IgG,
r  = 0.52, p = 0.001 and IgM, r = 0.37, p = 0.024).
Although the median FLC ratio was  similar in the groups of
patients  with and without cryoglobulins (p > 0.05) (see Table 2),
two  patients with cryoglobulins exhibited an increase in this
ratio.  The ﬁrst had an FLC ratio of 1.79 (kappa FLC = 66.30 mg/L
and  lambda FLC = 37.0 mg/L), and the second had an FLC ratio
of  3.51 (kappa FLC = 196.6 mg/L and lambda FLC = 56.0 mg/L).
There  was  a positive correlation between the FLC ratio and
the  IgG level (r = 0.54, p = 0.003) and between the FLC ratio and
the  IgM level (r = 0.38, p = 0.048) in the cryoglobulinemic patient
group.  Although the median FLC ratio was higher in patients
with  advanced ﬁbrosis (F3–F4) (p = 0.004), it remained in the
normal  range (see Fig. 1).
Immunoﬁxation  electrophoresis was performed in 17 sol-
ubilized  cryoglobulin samples from the 28 patients with
cryoglobulinemia (60.7%) who had enough material for this
analysis.  Fourteen cryoglobulins were immune complexes
containing IgM, IgG and kappa light chain, and three had only
one  type of immunoglobulin (see Table 3).
bda free light chains (FLC) in healthy control individuals
Cryoglobulin p value
352.8 ± 146.9 0.004
1918 ± 676.5 >0.05
146.0 (103.8–248.5) 0.014
18.8 (14.8–31.9) 0.001
20.4 (18.0–32.6) 0.003
0.90 (0.79–1.13) >0.05
 FLC as the median and IQR (mg/L).
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Fig. 1 – FLC ratio in HCV-infected patients presenting absent
to  moderate ﬁbrosis (F0–F2) and advanced ﬁbrosis (F3–F4).
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The National Council for Scientiﬁc and Technological Devel-orizontal lines represent the medians and interquartile
ange (25.0–75.0%). The normal FLC ratio range is 0.30–1.65.
iscussion
n the present study, we investigated serum biomarkers of B-
ell malignancy in Brazilian patients who were chronically
nfected with HCV. This virus infects and provokes dysfunc-
ion  in B-lymphocytes, which is primarily associated with
he  production of cryoglobulin, NOSA, and B-NHL. Moreover,
here  is a well-documented association between persistent
CV  infection and B-NHL that has been demonstrated by the
igh  frequency of B-NHL in cryoglobulinemic patients and its
egression following antiviral therapy.2–9
Conﬁrming our previous reports, cryoglobulinemia was  the
ain  extrahepatic manifestation of HCV infection in Brazil-
an  patients who  participated of this study.16,17 Furthermore,
e  veriﬁed that cryoglobulinemic patients produced more  IgA,
gM and both kappa and lambda FLC than did patients without
ryoglobulinemia. In cryoglobulinemic individuals, the lev-
ls  of both kappa and lambda FLC were strongly correlated
ith  the IgA, IgG and IgM levels, suggesting an intense poly-
lonal  production of these immunoglobulins. In contrast, a
ositive correlation was  observed between the serum levels
f  kappa FLC and IgG in non-cryoglobulinemic HCV-infected
atients. Furthermore, only a weak correlation was  observed
etween  serum levels of lambda FLC and levels of IgA, IgG and
gM  in non-cryoglobulinemic HCV-infected patients. Although
CV  infection causes persistent antigen stimulation and poly-
lonal  activation, it is more  vigorous in patients who produce
ryoglobulins. Interestingly, this increase in both the FLC
appa  and the FLC lambda did not alter FLC ratios of the
atients, conﬁrming its association with a polyclonal activa-
ion  of B-lymphocytes and absence of B-cell malignancy.
Although we  found an increased FLC ratio in two patients
ho  had cryoglobulinemia and high serum levels of kappa and
ambda  FLC, this ﬁnding may  be associated with the excessive
roduction of immunoglobulins in these subjects.114;1 8(6):638–642  641
The FLC ratio was  higher in HCV patients presenting
advanced liver ﬁbrosis. We  had previously demonstrated that
advanced  stage of ﬁbrosis in Brazilian patients is associated
with  cryoglobulinemia.21
Determination of the serum levels of kappa and lambda
FLC,  including the FLC ratio, is a valuable immunological tool
for  detecting the presence of polyclonal activation and mono-
clonal  dyscrasias of B-lymphocytes and plasma cells.10,12,22
Although chronic HCV infection has been associated with B-
malignancy, only two studies, both performed with French
patients,  investigated these biomarkers in cases of chronic
hepatitis C. They demonstrated an increase of kappa FLC
serum  levels in patients with mixed cryoglobulinemia, observ-
ing  an abnormal FLC ratio in patients with MC vasculitis
and B-NHL, with a signiﬁcant correlation between elevated
FLC  ratios and cryoglobulin level and severe HCV-related B-
NHL.14,15 In contrast, FLC was shown to be a potential sensitive
marker of polyclonal B-cell activation in a cohort of HIV-
infected  patients, who experienced increased risk of NHL.23
In our study, all HCV-infected patients with cryoglobuline-
mia  were  asymptomatic and did not have documentation of
B-cell  malignancy in their medical history. Thus, our observa-
tion  of normal FLC ratios in these subjects is in accordance
with one of the previous French studies that showed unal-
tered  FLC ratios in patients with asymptomatic MC.  Also in
accordance  with the results of the same French study, we
observed  a positive correlation between IgM and kappa FLC
levels  in these individuals.14 In contrast, we  demonstrated
that serum levels of kappa FLC were strongly correlated with
IgA  and IgG levels in patients with cryoglobulinemia. We  also
observed  a strong correlation between lambda FLC levels and
levels  of IgA, IgG and IgM in these subjects. Nonetheless,
the correlation of lambda FLC levels and the levels of these
three  immunoglobulins was  also observed in patients without
cryoglobulins, supporting the hypothesis that environmental
and  ethnic factors may  cause the immunological differences
observed between Brazilian and French patients with chronic
HCV  infection.
We  did not verify a monoclonal pattern of IFE in the solubi-
lized  cryoglobulins from HCV-patients. These cryoprecipitable
immune complexes were mainly formed by IgM plus IgG or
IgA  and kappa light chain, corresponding to type III mixed
cryoglobulins.
In  conclusion, most HCV cryoglobulinemic patients
included in our study presented mixed cryoglobulins and
a  vigorous polyclonal activation of B-lymphocytes due to
chronic  HCV infection and persistent immune stimulation.
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